查看購物車
  • Simplified Chinese
  • English
  • Japanese
治療性疫苗市場規模及預測 2021 - 2031、全球及地區佔有率、趨勢及成長機會分析報告範圍：依產品、技術、最終用戶及地理分類
市場調查報告書
商品編碼
1666225

治療性疫苗市場規模及預測 2021 - 2031、全球及地區佔有率、趨勢及成長機會分析報告範圍：依產品、技術、最終用戶及地理分類

Therapeutic Vaccines Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product, Technology, End User, and Geography
出版日期: | 出版商: The Insight Partners | 英文 207 Pages | 訂單完成後即時交付

價格

治療性疫苗市場規模預計將從2024年的12.4億美元成長到2031年的29.3億美元；預計 2024-2031 年期間的複合年成長率為 13.0%。慢性病發病率的上升以及疫苗開發的投資和資金的增加是推動治療性疫苗市場擴大的值得注意的因素。然而，監管挑戰阻礙了治療性疫苗市場的成長。

使用傳統技術無法開發可能引起大流行的新興病原體的疫苗。因此，開發能夠快速應對大流行威脅並有效適應應對新出現的變種措施的平台非常重要。創新疫苗平台（例如mRNA疫苗、基於免疫材料的疫苗技術、奈米藥物傳遞系統和基於病毒載體的疫苗）正在徹底改變治療性疫苗的發展。此外，向更有效率和可客製化的疫苗技術的轉變使得可以針對多種疾病（包括癌症、自體免疫疾病和傳染病）的疫苗的開發成為可能。 mRNA COVID-19疫苗技術的成功展示了mRNA技術在傳染病之外的治療應用（包括癌症和慢性感染）中的潛力。這些平台可以實現更快、更靈活、更好的可擴展的疫苗生產，從而加速新型治療性疫苗的開發。

研究人員正在為未來的應用程式開發新平台。例如，哈佛大學 Wyss 研究所的研究小組正在開發一個名為 OMNIVAX 的先驅疫苗平台。這種「一流的基於免疫材料」的疫苗技術旨在創造安全有效的針對病毒和細菌感染的治療和預防疫苗。注射後，OMNIVAX 疫苗會建立一個支架來吸引樹突狀免疫細胞，並進行編程以針對特定抗原。然後細胞被釋放，接著遷移到附近的淋巴結，在那裡啟動全身和長期的免疫反應。使用模組化技術，可以將多種抗原整合到單一 OMNIVAX 疫苗中。疫苗技術的進步可能會在未來幾年為治療性疫苗市場帶來新的趨勢。

基於最終用戶的洞察

根據最終用戶，治療性疫苗市場分為醫院、診所和其他。 2024 年，醫院部門佔據了治療性疫苗最大的市場佔有率。醫院配備了實施針對癌症和自體免疫疾病的專門治療所需的先進基礎設施。隨著癌症等慢性病在全球的發生率持續上升，醫院對這些治療的需求持續存在。醫院提供全面的護理，包括診斷服務、治療和治療後監測，所有這些對於接受治療性疫苗治療的患者都至關重要。此外，醫院研究和臨床試驗的激增也促進了該領域治療性疫苗市場的擴張。許多治療性疫苗在醫院環境中進行試驗，使醫療保健專業人員能夠及時了解新疫苗和治療方法的發展，從而推動治療性疫苗市場的成長。

世界衛生組織（WHO）、全球癌症事實與數據以及美國癌症協會是編寫治療性疫苗市場報告時參考的主要和次要來源。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 關鍵見解

第3章：研究方法

  • 二次研究
  • 初步研究
    • 假設表述：
    • 宏觀經濟因素分析：
    • 發育基數：
    • 數據三角測量：
    • 國家級資料：

第 4 章：治療性疫苗市場格局

  • 概述
  • PEST分析

第 5 章：治療性疫苗市場 - 主要市場動態

  • 治療性疫苗市場 - 主要市場動態
  • 市場促進因素
    • 慢性病盛行率上升
    • 增加疫苗研發的投資與資金
  • 市場限制
    • 監管挑戰
  • 市場機會
    • 擴展產品線
  • 未來趨勢
    • 疫苗技術的進步
  • 促進因素和限制因素的影響：

第 6 章：治療性疫苗市場 - 全球市場分析

  • 治療性疫苗市場收入，2021-2031 年
  • 治療性疫苗市場預測分析

第 7 章：治療性疫苗市場分析 - 按產品

  • 癌症疫苗
  • 傳染病疫苗
  • 其他

第 8 章：治療性疫苗市場分析 - 按技術

  • 同種異體疫苗
  • 自體疫苗

第 9 章：治療性疫苗市場分析 - 按最終用戶

  • 醫院
  • 診所
  • 其他

第 10 章：治療性疫苗市場 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 亞太地區其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 11 章：治療性疫苗市場-產業格局

  • 概述
  • 治療性疫苗市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第 12 章：公司簡介

  • Dendreon
  • BioNTech SE
  • Serum Institute of India Pvt. Ltd
  • Merck & Co Inc
  • Amgen Inc
  • ISA Pharmaceuticals BV
  • INOVIO Pharmaceuticals Inc
  • Transgene SA
  • THERAVECTYS SA
  • CureVac SE

第 13 章：附錄

Product Code: TIPRE00039849

The therapeutic vaccines market size is expected to grow from US$ 1.24 billion in 2024 to US$ 2.93 billion by 2031; it is projected to register a CAGR of 13.0% during 2024-2031. The rising prevalence of chronic diseases, and increasing investments and funding for vaccine development are noteworthy factors contributing to the expansion of the therapeutic vaccines market size. However, regulatory challenges hinder the therapeutic vaccines market growth.

Developing vaccines against emerging pathogens that possess the potential to cause pandemics is not feasible using conventional technologies. As a result, it is important to develop platforms that can respond rapidly to pandemic threats and adapt effectively to measures taken to tackle emerging variants. Innovative vaccine platforms-such as mRNA vaccines, immuno-material-based vaccine technology, nano-drug delivery systems, and viral vector-based vaccines-are revolutionizing the development of therapeutic vaccines. Further, the shift toward more efficient and customizable vaccine technologies has enabled the development of vaccines that can target several diseases, including cancers, autoimmune conditions, and infectious diseases. The success of mRNA COVID-19 vaccine technology showcases promises in the potential of mRNA technology for therapeutic applications beyond infectious diseases, including cancer and chronic infections. These platforms allow for quicker, more flexible, and better scalable vaccine production, accelerating the development of new therapeutic vaccines.

Researchers are developing novel platforms for future applications. For instance, a research team at the Wyss Institute at Harvard University is developing a pioneering vaccine platform known as OMNIVAX. This "first-in-class immuno-material-based" vaccine technology aims to create safe and effective therapeutic and prophylactic vaccines against viral and bacterial infections. Upon injection, OMNIVAX vaccines establish a scaffold to attract dendritic immune cells, programming them to target a specific antigen. The cells are then released, followed by their migration to nearby lymph nodes, where they initiate a systemic and prolonged immune response. Using modular technology, multiple antigens can be incorporated into a single OMNIVAX vaccine. The advancements in vaccine technology are likely to bring new trends in the therapeutic vaccines market in the coming years.

End User-Based Insights

Based on end user, the therapeutic vaccines market is segmented into hospitals, clinics, and others. The hospitals segment held the largest therapeutic vaccines market share in 2024. Therapeutic vaccines are increasingly being recognized as a critical part of the treatment of cancer and other chronic diseases, which are frequently managed in hospital settings. Hospitals are equipped with the advanced infrastructure required to administer specialized therapies against cancer and autoimmune diseases. As the prevalence of chronic diseases, including cancer, continues to rise globally, hospitals generate a persistent demand for these treatments. Hospitals offer comprehensive care, including diagnostic services, treatment, and post-therapy monitoring, all of which are crucial for patients undergoing therapeutic vaccine treatments. Additionally, an upsurge in hospital-based research and clinical trials contributes to the expansion of the therapeutic vaccines market for this segment. Many therapeutic vaccines undergo trials within hospital environments, enabling healthcare professionals to stay updated on the development of new vaccines and treatments, fueling the therapeutic vaccines market growth.

World Health Organization's (WHO), Global Cancer Facts & Figures, and the American Cancer Society are among the primary and secondary sources referred to while preparing the therapeutic vaccines market report.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Therapeutic Vaccines Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Therapeutic Vaccines Market - Key Market Dynamics

  • 5.1 Therapeutic Vaccines Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Rising Prevalence of Chronic Conditions
    • 5.2.2 Increasing Investments and Funding for Vaccine Development
  • 5.3 Market Restraints
    • 5.3.1 Regulatory Challenges
  • 5.4 Market Opportunities
    • 5.4.1 Extending Product Pipeline
  • 5.5 Future Trends
    • 5.5.1 Advancements in Vaccine Technology
  • 5.6 Impact of Drivers and Restraints:

6. Therapeutic Vaccines Market - Global Market Analysis

  • 6.1 Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
  • 6.2 Therapeutic Vaccines Market Forecast Analysis

7. Therapeutic Vaccines Market Analysis - by Product

  • 7.1 Cancer Vaccines
    • 7.1.1 Overview
    • 7.1.2 Cancer Vaccines: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • 7.2 Infectious Disease Vaccines
    • 7.2.1 Overview
    • 7.2.2 Infectious Disease Vaccines: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • 7.3 Others
    • 7.3.1 Overview
    • 7.3.2 Others: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)

8. Therapeutic Vaccines Market Analysis - by Technology

  • 8.1 Allogenic Vaccine
    • 8.1.1 Overview
    • 8.1.2 Allogenic Vaccine: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • 8.2 Autologous Vaccine
    • 8.2.1 Overview
    • 8.2.2 Autologous Vaccine: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)

9. Therapeutic Vaccines Market Analysis - by End User

  • 9.1 Hospitals
    • 9.1.1 Overview
    • 9.1.2 Hospitals: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • 9.2 Clinics
    • 9.2.1 Overview
    • 9.2.2 Clinics: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • 9.3 Others
    • 9.3.1 Overview
    • 9.3.2 Others: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)

10. Therapeutic Vaccines Market - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Therapeutic Vaccines Market Overview
    • 10.1.2 North America: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
      • 10.1.2.1 North America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
      • 10.1.2.2 North America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
      • 10.1.2.3 North America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
    • 10.1.3 North America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 10.1.3.1 United States: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.1.3.1.1 United States: Therapeutic Vaccines Market Breakdown, by Product
        • 10.1.3.1.2 United States: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.1.3.1.3 United States: Therapeutic Vaccines Market Breakdown, by End User
      • 10.1.3.2 Canada: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.1.3.2.1 Canada: Therapeutic Vaccines Market Breakdown, by Product
        • 10.1.3.2.2 Canada: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.1.3.2.3 Canada: Therapeutic Vaccines Market Breakdown, by End User
      • 10.1.3.3 Mexico: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.1.3.3.1 Mexico: Therapeutic Vaccines Market Breakdown, by Product
        • 10.1.3.3.2 Mexico: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.1.3.3.3 Mexico: Therapeutic Vaccines Market Breakdown, by End User
  • 10.2 Europe
    • 10.2.1 Europe Therapeutic Vaccines Market Overview
    • 10.2.2 Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
      • 10.2.2.1 Europe: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
      • 10.2.2.2 Europe: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
      • 10.2.2.3 Europe: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
    • 10.2.3 Europe: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 10.2.3.1 Germany: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.2.3.1.1 Germany: Therapeutic Vaccines Market Breakdown, by Product
        • 10.2.3.1.2 Germany: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.2.3.1.3 Germany: Therapeutic Vaccines Market Breakdown, by End User
      • 10.2.3.2 United Kingdom: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.2.3.2.1 United Kingdom: Therapeutic Vaccines Market Breakdown, by Product
        • 10.2.3.2.2 United Kingdom: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.2.3.2.3 United Kingdom: Therapeutic Vaccines Market Breakdown, by End User
      • 10.2.3.3 France: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.2.3.3.1 France: Therapeutic Vaccines Market Breakdown, by Product
        • 10.2.3.3.2 France: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.2.3.3.3 France: Therapeutic Vaccines Market Breakdown, by End User
      • 10.2.3.4 Italy: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.2.3.4.1 Italy: Therapeutic Vaccines Market Breakdown, by Product
        • 10.2.3.4.2 Italy: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.2.3.4.3 Italy: Therapeutic Vaccines Market Breakdown, by End User
      • 10.2.3.5 Spain: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.2.3.5.1 Spain: Therapeutic Vaccines Market Breakdown, by Product
        • 10.2.3.5.2 Spain: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.2.3.5.3 Spain: Therapeutic Vaccines Market Breakdown, by End User
      • 10.2.3.6 Rest of Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.2.3.6.1 Rest of Europe: Therapeutic Vaccines Market Breakdown, by Product
        • 10.2.3.6.2 Rest of Europe: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.2.3.6.3 Rest of Europe: Therapeutic Vaccines Market Breakdown, by End User
  • 10.3 Asia Pacific
    • 10.3.1 Asia Pacific Therapeutic Vaccines Market Overview
    • 10.3.2 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
      • 10.3.2.1 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
      • 10.3.2.2 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
      • 10.3.2.3 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
    • 10.3.3 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 10.3.3.1 China: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.3.3.1.1 China: Therapeutic Vaccines Market Breakdown, by Product
        • 10.3.3.1.2 China: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.3.3.1.3 China: Therapeutic Vaccines Market Breakdown, by End User
      • 10.3.3.2 Japan: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.3.3.2.1 Japan: Therapeutic Vaccines Market Breakdown, by Product
        • 10.3.3.2.2 Japan: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.3.3.2.3 Japan: Therapeutic Vaccines Market Breakdown, by End User
      • 10.3.3.3 India: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.3.3.3.1 India: Therapeutic Vaccines Market Breakdown, by Product
        • 10.3.3.3.2 India: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.3.3.3.3 India: Therapeutic Vaccines Market Breakdown, by End User
      • 10.3.3.4 South Korea: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.3.3.4.1 South Korea: Therapeutic Vaccines Market Breakdown, by Product
        • 10.3.3.4.2 South Korea: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.3.3.4.3 South Korea: Therapeutic Vaccines Market Breakdown, by End User
      • 10.3.3.5 Australia: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.3.3.5.1 Australia: Therapeutic Vaccines Market Breakdown, by Product
        • 10.3.3.5.2 Australia: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.3.3.5.3 Australia: Therapeutic Vaccines Market Breakdown, by End User
      • 10.3.3.6 Rest of APAC: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.3.3.6.1 Rest of APAC: Therapeutic Vaccines Market Breakdown, by Product
        • 10.3.3.6.2 Rest of APAC: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.3.3.6.3 Rest of APAC: Therapeutic Vaccines Market Breakdown, by End User
  • 10.4 Middle East & Africa
    • 10.4.1 Middle East & Africa Therapeutic Vaccines Market Overview
    • 10.4.2 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
      • 10.4.2.1 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
      • 10.4.2.2 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
      • 10.4.2.3 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
    • 10.4.3 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 10.4.3.1 Saudi Arabia: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.4.3.1.1 Saudi Arabia: Therapeutic Vaccines Market Breakdown, by Product
        • 10.4.3.1.2 Saudi Arabia: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.4.3.1.3 Saudi Arabia: Therapeutic Vaccines Market Breakdown, by End User
      • 10.4.3.2 South Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.4.3.2.1 South Africa: Therapeutic Vaccines Market Breakdown, by Product
        • 10.4.3.2.2 South Africa: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.4.3.2.3 South Africa: Therapeutic Vaccines Market Breakdown, by End User
      • 10.4.3.3 United Arab Emirates: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.4.3.3.1 United Arab Emirates: Therapeutic Vaccines Market Breakdown, by Product
        • 10.4.3.3.2 United Arab Emirates: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.4.3.3.3 United Arab Emirates: Therapeutic Vaccines Market Breakdown, by End User
      • 10.4.3.4 Rest of Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.4.3.4.1 Rest of Middle East & Africa: Therapeutic Vaccines Market Breakdown, by Product
        • 10.4.3.4.2 Rest of Middle East & Africa: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.4.3.4.3 Rest of Middle East & Africa: Therapeutic Vaccines Market Breakdown, by End User
  • 10.5 South & Central America
    • 10.5.1 South & Central America Therapeutic Vaccines Market Overview
    • 10.5.2 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
      • 10.5.2.1 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
      • 10.5.2.2 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
      • 10.5.2.3 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
    • 10.5.3 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 10.5.3.1 Brazil: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.5.3.1.1 Brazil: Therapeutic Vaccines Market Breakdown, by Product
        • 10.5.3.1.2 Brazil: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.5.3.1.3 Brazil: Therapeutic Vaccines Market Breakdown, by End User
      • 10.5.3.2 Argentina: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.5.3.2.1 Argentina: Therapeutic Vaccines Market Breakdown, by Product
        • 10.5.3.2.2 Argentina: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.5.3.2.3 Argentina: Therapeutic Vaccines Market Breakdown, by End User
      • 10.5.3.3 Rest of South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.5.3.3.1 Rest of South & Central America: Therapeutic Vaccines Market Breakdown, by Product
        • 10.5.3.3.2 Rest of South & Central America: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.5.3.3.3 Rest of South & Central America: Therapeutic Vaccines Market Breakdown, by End User

11. Therapeutic Vaccines Market - Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in the Therapeutic Vaccines Market
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Dendreon
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 BioNTech SE
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Serum Institute of India Pvt. Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Merck & Co Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Amgen Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 ISA Pharmaceuticals BV
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 INOVIO Pharmaceuticals Inc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Transgene SA
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 THERAVECTYS SA
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 CureVac SE
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. Therapeutic Vaccines Market Segmentation
  • Table 2. North America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 3. North America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 4. North America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 5. United States: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 6. United States: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 7. United States: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 8. Canada: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 9. Canada: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 10. Canada: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 11. Mexico: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 12. Mexico: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 13. Mexico: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 14. Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 15. Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 16. Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 17. Germany: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 18. Germany: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 19. Germany: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 20. United Kingdom: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 21. United Kingdom: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 22. United Kingdom: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 23. France: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 24. France: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 25. France: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 26. Italy: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 27. Italy: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 28. Italy: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 29. Spain: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 30. Spain: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 31. Spain: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 32. Rest of Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 33. Rest of Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 34. Rest of Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 35. Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 36. Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 37. Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 38. China: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 39. China: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 40. China: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 41. Japan: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 42. Japan: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 43. Japan: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 44. India: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 45. India: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 46. India: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 47. South Korea: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 48. South Korea: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 49. South Korea: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 50. Australia: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 51. Australia: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 52. Australia: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 53. Rest of APAC: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 54. Rest of APAC: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 55. Rest of APAC: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 56. Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 57. Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 58. Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 59. Saudi Arabia: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 60. Saudi Arabia: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 61. Saudi Arabia: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 62. South Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 63. South Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 64. South Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 65. United Arab Emirates: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 66. United Arab Emirates: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 67. United Arab Emirates: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 68. Rest of Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 69. Rest of Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 70. Rest of Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 71. South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 72. South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 73. South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 74. Brazil: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 75. Brazil: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 76. Brazil: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 77. Argentina: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 78. Argentina: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 79. Argentina: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 80. Rest of South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 81. Rest of South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 82. Rest of South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 83. Recent Organic Growth Strategies in the Therapeutic Vaccines Market
  • Table 84. Recent Inorganic Growth Strategies in the Therapeutic Vaccines Market
  • Table 85. Glossary of Terms, Therapeutic Vaccines Market

List Of Figures

  • Figure 1. Therapeutic Vaccines Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
  • Figure 5. Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 6. Therapeutic Vaccines Market Share (%) - by Product (2024 and 2031)
  • Figure 7. Cancer Vaccines: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 8. Infectious Disease Vaccines: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 9. Others: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 10. Therapeutic Vaccines Market Share (%) - by Technology (2024 and 2031)
  • Figure 11. Allogenic Vaccine: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 12. Autologous Vaccine: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 13. Therapeutic Vaccines Market Share (%) - by End User (2024 and 2031)
  • Figure 14. Hospitals: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 15. Clinics: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 16. Others: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 17. North America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 18. North America: Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 19. United States: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 20. Canada: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 21. Mexico: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 22. Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 23. Europe: Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 24. Germany: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 25. United Kingdom: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 26. France: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 27. Italy: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 28. Spain: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 29. Rest of Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 30. Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 31. Asia Pacific: Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 32. China: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 33. Japan: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 34. India: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 35. South Korea: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 36. Australia: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 37. Rest of APAC: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 38. Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 39. Middle East & Africa: Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 40. Saudi Arabia: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 41. South Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 42. United Arab Emirates: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 43. Rest of Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 44. South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 45. South & Central America: Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 46. Brazil: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 47. Argentina: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 48. Rest of South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 49. Growth Strategies in the Therapeutic Vaccines Market